Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DY0D | ISIN: US1508376076 | Ticker-Symbol: LSRM
Frankfurt
04.11.24
08:09 Uhr
0,763 Euro
-0,015
-1,87 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CEL-SCI CORPORATION Chart 1 Jahr
5-Tage-Chart
CEL-SCI CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
0,7370,76521:45
0,7390,76321:45

Aktuelle News zur CEL-SCI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.10.CEL-SCI files to sell 1M shares of common stock for holders5
29.09.CEL-SCI Aktie: Biotechfirma vor Quartalsbericht unter Druck662Die CEL-SCI Corporation, ein Biotechnologieunternehmen im klinischen Stadium, steht vor wichtigen Entwicklungen. Der Aktienkurs des Unternehmens, das sich auf Immuntherapien gegen Krebs und andere Krankheiten...
► Artikel lesen
16.09.CEL-SCI Corporation: CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation3665-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who...
► Artikel lesen
10.09.CEL-SCI Corporation: CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress299Data to be presented on Saturday, September 14 and published via a press release before the open of market on Monday, September 16 CEL-SCI Corporation (NYSE American: CVM) today reported it...
► Artikel lesen
04.09.CEL-SCI gains UK pediatric waiver for cancer treatment2
04.09.Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy - Kursziel: USD6.20247Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH 04.09.2024 / 12:31 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The...
► Artikel lesen
30.08.CEL SCI CORP - S-8, Securities to be offered to employees in employee benefit plans2
15.08.Cel-Sci GAAP EPS of -$0.42 misses by $0.315
15.08.CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results170VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. Clinical...
► Artikel lesen
26.07.CEL SCI CORP - 8-K, Current Report9
26.07.XFRA LSRM: WIEDERAUFNAHME/RESUMPTION303FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
26.07.XFRA LSRM: AUSSETZUNG/SUSPENSION313DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCEL-SCI CORP. NEW...
► Artikel lesen
26.07.CEL-SCI stock rallies 40% on Multikine study analysis results13
26.07.CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results200VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte Interleukin...
► Artikel lesen
08.07.CEL-SCI names Robert Watson as chair5
18.06.CEL-SCI Corporation: CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population295Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs...
► Artikel lesen
11.06.Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy - Kursziel: USD6.20304Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to CEL-SCI Corporation Company Name: CEL-SCI Corporation ISIN:...
► Artikel lesen
16.05.CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results395VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical...
► Artikel lesen
15.05.CEL SCI CORP - 10-Q, Quarterly Report7
08.05.Why CEL-SCI (CVM) Shares Are Trading Higher16
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1